RCM
CATX icon

Rotella Capital Management’s Perspective Therapeutics CATX Stock Holding History

Rotella Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,676
Closed -$16K – 50
2015
Q4 		$16K Sell
1,676
-3,383
-67% -$42.1K 0.01% 395
2015
Q3 		$71K Buy
5,059
+1,879
+59% +$27.1K 0.02% 463
2015
Q2 		$47K Buy
+3,180
New +$51.5K 0.04% 375

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return

Rotella Capital Management's CATX Position: Q1 2016 in Review

Rotella Capital Management sold out of Perspective Therapeutics (CATX) in Q1 2016, closing a stake of 1,676 shares — an estimated $16K sold.

Rotella Capital Management first reported a position in CATX in Q2 2015 and held it in 3 quarters. The position peaked at $71K in Q3 2015. 24 funds tracked by Wall St. Rank hold CATX as of Q1 2016.

  • Rotella Capital Management reported no remaining Perspective Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 1,676 Perspective Therapeutics shares in Q1 2016, an estimated $16K.
  • Rotella Capital Management first reported a position in Perspective Therapeutics in Q2 2015 and held it in 3 quarters.
  • Rotella Capital Management's Perspective Therapeutics position peaked at $71K in Q3 2015.
  • 24 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.